课题基金 / 基金详情

Large scale lentiviral vector production

Large scale lentiviral vector production
大规模慢病毒载体生产
批准号:
BB/N003853/1
负责人:
Farzin Farzaneh
金额:
$74.52万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2015
资助国家:
英国
项目状态:
已结题
起止时间:
2015 至 --

项目摘要

项目成果

Farzin Farzaneh的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Lentiviral vectors (LV) are remarkable in their ability to insert their genetic payload into a target cell's genome. This affects apermanent genetic change in the target which is propagated through to its progeny. While there are several means ofgenetic modification, few are capable of permanent modification of target cells. Amongst all vectors for gene delivery, LVare unique in unparalleled efficiency, safety, lack of toxicity and ability to modify non-dividing target cells. They havetherefore come to be recognised as a key reagent required for the efficient development of the burgeoning cell therapy, aswell as gene therapy industries. However, although LV represent a well understood and robust technology, there is nomanufacturing methodology for very large-scale LV production. This is now an acknowledged bottle-neck both for clinicaltrials and for commercial exploitation of many cell and gene therapy products in current development. We propose toaddress this unmet need
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1182/blood.v130.suppl_1.887.887
发表时间: 2017-12
期刊: Blood
影响因子: 20.3
作者: [C. Graham;D. Yallop;A. Jóźwik;P. Patten;A. Dunlop;R. Ellard;Orla Stewart;V. Potter;V. Metaxa;S. Kassam;F. Farzaneh;S. Devereux;A. Pagliuca;A. Zinai;F. Binlich;S. Dupouy;Anne Philippe;S. Balandraud;F. Dubois;C. Konto;Premal H. Patel;G. Mufti;R. Benjamin]
通讯作者: C. Graham;D. Yallop;A. Jóźwik;P. Patten;A. Dunlop;R. Ellard;Orla Stewart;V. Potter;V. Metaxa;S. Kassam;F. Farzaneh;S. Devereux;A. Pagliuca;A. Zinai;F. Binlich;S. Dupouy;Anne Philippe;S. Balandraud;F. Dubois;C. Konto;Premal H. Patel;G. Mufti;R. Benjamin
Allogeneic Anti-CD19 CAR T Cells Manufactured from Healthy Donors Provide a Unique Cellular Product with Distinct Phenotypic Characteristics Compared to CAR T Cells Generated from Patients with Mature B Cell Malignancies
与来自成熟 B 细胞恶性肿瘤患者的 CAR T 细胞相比,来自健康捐赠者的同种异体抗 CD19 CAR T 细胞提供了具有独特表型特征的独特细胞产品
DOI: 10.1182/blood-2019-123018
发表时间: 2019
期刊: Blood
影响因子: 20.3
作者: [Graham C]
通讯作者: Graham C
Efficient Ex Vivo Expansion of ?d T-Cells from AML Patients Requires Elimination of Circulating Leukemic Blasts
AML 患者体内 ?d T 细胞的高效体外扩增需要消除循环白血病母细胞
DOI: 10.36959/486/327
发表时间: 2020
期刊: Advances in Leukemia Research and Treatment
影响因子: --
作者: [Ana C P]
通讯作者: Ana C P
BRIC: Packaging cell lines for inherently manufacturable viral vectors
  • 批准号:
    BB/E005896/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $32.02万
  • 财政年份:
    2007
  • 负责人:
    Farzin Farzaneh
  • 依托单位:
Second Generation Bio-Lentivir Packaging Cell Line for Facile Lentivirus Production
  • 批准号:
    EP/D500346/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $25.5万
  • 财政年份:
    2006
  • 负责人:
    Farzin Farzaneh
  • 依托单位:
SPONTANEOUSLY BIOTINYLATED LENTIVIRAL VECTORS FOR ENVELOPE INDEPENDENT TARGETING OF INFECTION
  • 批准号:
    BB/D014301/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $25.12万
  • 财政年份:
    2006
  • 负责人:
    Farzin Farzaneh
  • 依托单位:
国内基金
海外基金
基于热量传递的传统固态发酵过程缩小(Scale-down)机理及调控
  • 批准号:
    22108101
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    靳光远
  • 依托单位:
基于Multi-Scale模型的轴流血泵瞬变流及空化机理研究
  • 批准号:
    31600794
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    22.0万元
  • 批准年份:
    2016
  • 负责人:
    荆腾
  • 依托单位:
基于异构医学影像数据的深度挖掘技术及中枢神经系统重大疾病的精准预测
  • 批准号:
    61672236
  • 项目类别:
    面上项目
  • 资助金额:
    64.0万元
  • 批准年份:
    2016
  • 负责人:
    王骏
  • 依托单位:
城镇居民亚健康状态的评价方法学及健康管理模式研究
  • 批准号:
    81172775
  • 项目类别:
    面上项目
  • 资助金额:
    14.0万元
  • 批准年份:
    2011
  • 负责人:
    许军
  • 依托单位: